FDA's Biological Response Modifiers Advisory Committee
Executive Summary
Will meet Jan. 16-17. On the first day, Cytogen's OncoScint OV 103 for the diagnosis of primary and recurrent ovarian carcinoma will be reviewed. OncoScint is the first Cytogen product to come before an advisory committee. On Jan. 17, the committee will discuss for the second time, Cetus' Proleukin (interleukin-2) for the treatment of metastatic renal cell carcinoma. In July 1990, the committee suggested that Cetus reanalyze its efficacy data and conduct new studies ("The Pink Sheet" Aug. 6, 1990, p. 6). The company complied and supplied the results of its reanalysis to FDA in December 1990. The meeting, at the Bethesda, Md. Holiday Inn, 8120 Wisconsin Ave. will begin at 10 a.m. on the 16th and at 8:30 a.m. the following day. The committee also will meet in a closed session on Jan. 17.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth